Ixabepilone is under clinical development by R-Pharm US and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ixabepilone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ixabepilone (Ixempra, Ixemprya) is a microtubule inhibitor and a type of epothilone analog belonging to the class of antineoplastic agents. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. It is being developed based on DRP platform technology.
It is under development for the treatment of metastatic breast cancer and HER-2 negative breast cancer, HER-2 positive beast cancer, triple-negative breast cancer in EU, epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancers.
For a complete picture of Ixabepilone’s drug-specific PTSR and LoA scores, buy the report here.